Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 6.

Siebenhüner, A; Winder, T; Petrowsky, Henrik; Clavien, Pierre-Alain; Pestalozzi, Bernhard C (2015). Therapie des metastasierten kolorektalen Karzinoms am Beispiel von metachronen Lebermetastasen. CME, 104(2):67-79.

Pircher, M; Winder, T; Pestalozzi, B C; Petrausch, U (2015). Immuntherapien – eine neue tragende Säule der Onkologie. PharmaJournal, 20:5-11.

Szkandera, J; Pichler, M; Absenger, G; Stotz, M; Weissmueller, M; Samonigg, H; Asslaber, M; Lax, S; Leitner, G; Winder, T; Renner, W; Gerger, A (2014). A functional germline variant in GLI1 implicates Hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients. Clinical Cancer Research, 20(6):1687-1697.

Winder, T; Giamas, G; Wilson, P M; Zhang, W; Bohanes, P; Ning, Y; Gerger, A; Stebbing, J; Lenz, H-J (2014). Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients Q1 treated with tamoxifen. Pharmacogenomics Journal, 14:28-34.

Pohl, A; El-Khoueiry, A; Yang, D; Zhang, W; Lurje, G; Ning, Y; Winder, T; Hu-Lieskoven, S; Iqbal, S; Danenberg, K D; Kahn, M; Teo, J L; Shriki, J; Stebbing, J; Lenz, H J (2013). Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics Journal, 13(2):173-180.

Zhang, W; Winder, T; Ning, Y; Pohl, A; Yang, D; Kahn, M; Lurje, G; LaBonte, M J; Wilson, P M; Gordon, M A; Hu-Lieskovan, S; Mauro, D J; Langer, C; Rowinsky, E K; Lenz, H-J (2011). A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Annals of Oncology, 22(1):104-109.

This list was generated on Sat Jul 20 18:50:24 2019 CEST.